Bart M. Schwartz

HMS Holdings Corp. engages in the provision of cost containment and analytical solutions in the healthcare marketplace. It uses healthcare data technology, analytics, and related services to deliver coordination of benefits, payment, population risk intelligence, care management, and consumer engagement solutions to help payers reduce costs, and improve healthcare outcomes. The company was founded in 1974 and is headquartered in Irving, TX.

SolutionPoint International, Inc. provides security and identity solutions. The company was founded by Joseph R. Rosetti and Anthony M. Lanza in 2010 and is headquartered in New York, NY.

Guidepost Solutions LLC provides investigative and security consulting services. It offers global investigations, compliance, monitoring, and security and technology consulting solutions for clients in a wide range of industries. The firm provides security, investigative, compliance and monitoring leadership for critical client needs. The company was founded by Bart M. Schwartz in 2010 and is headquartered in New York, NY.

Police Athletic League, Inc. is a non-profit organization, which engages in the provision of recreation services. It offers programs from head start, day care and universal pre-K programs to elementary and middle school after-school programs; and summer day camps and summer play streets. The company was founded by Arthur Woods in 1914 and is headquartered in New York, NY.

Decision Strategies LLC provides security consulting services. It offers business intelligence, risk and crisis management, background and due diligence inquiry, security audit, security, and proprietary information protection services. The company serves corporations, law firms, financial institutions, government agencies, foreign governments and businesses & private individuals. Decision Strategies was founded in 1997 and is located in Oakton, VA.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.